137 related articles for article (PubMed ID: 32232958)
21. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
22. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
[TBL] [Abstract][Full Text] [Related]
23. Crizotinib inhibition of
Bebb DG; Agulnik J; Albadine R; Banerji S; Bigras G; Butts C; Couture C; Cutz JC; Desmeules P; Ionescu DN; Leighl NB; Melosky B; Morzycki W; Rashid-Kolvear F; Lab C; Sekhon HS; Smith AC; Stockley TL; Torlakovic E; Xu Z; Tsao MS
Curr Oncol; 2019 Aug; 26(4):e551-e557. PubMed ID: 31548824
[TBL] [Abstract][Full Text] [Related]
24. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
Gobbini E; Chiari R; Pizzutillo P; Bordi P; Ghilardi L; Pilotto S; Osman G; Cappuzzo F; Cecere F; Riccardi F; Scotti V; Martelli O; Borra G; Maiello E; Rossi A; Graziano P; Gregorc V; Casartelli C; Sergi C; Del Conte A; Delmonte A; Bareggi C; Cortinovis D; Rizzo P; Tabbò F; Rossi G; Bria E; Galetta D; Tiseo M; Di Maio M; Novello S
Clin Transl Oncol; 2020 Mar; 22(3):294-301. PubMed ID: 31630357
[TBL] [Abstract][Full Text] [Related]
25. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
Shaw AT; Riely GJ; Bang YJ; Kim DW; Camidge DR; Solomon BJ; Varella-Garcia M; Iafrate AJ; Shapiro GI; Usari T; Wang SC; Wilner KD; Clark JW; Ou SI
Ann Oncol; 2019 Jul; 30(7):1121-1126. PubMed ID: 30980071
[TBL] [Abstract][Full Text] [Related]
26. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
28. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.
Frampton JE
Drugs; 2013 Dec; 73(18):2031-51. PubMed ID: 24288180
[TBL] [Abstract][Full Text] [Related]
29. Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
Mizugaki H; Hamada A; Shibata T; Hosoda F; Nakamura H; Okuma Y; Shukuya T; Umemura S; Horiike A; Fukui T; Kogure Y; Daga H; Urata Y; Yamada K; Saeki S; Fujisaka Y; Nakamura Y; Sato M; Yoshida T; Hotta T; Oizumi S; Fujiwara Y; Ohe Y; Fujiwara Y
Lung Cancer; 2019 Feb; 128():20-25. PubMed ID: 30642448
[TBL] [Abstract][Full Text] [Related]
30. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
[No Abstract] [Full Text] [Related]
31. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Shaw AT; Kim DW; Nakagawa K; Seto T; Crinó L; Ahn MJ; De Pas T; Besse B; Solomon BJ; Blackhall F; Wu YL; Thomas M; O'Byrne KJ; Moro-Sibilot D; Camidge DR; Mok T; Hirsh V; Riely GJ; Iyer S; Tassell V; Polli A; Wilner KD; Jänne PA
N Engl J Med; 2013 Jun; 368(25):2385-94. PubMed ID: 23724913
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
33. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
Morris TA; Khoo C; Solomon BJ
Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
[TBL] [Abstract][Full Text] [Related]
34. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
35. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.
Groenland SL; Geel DR; Janssen JM; de Vries N; Rosing H; Beijnen JH; Burgers JA; Smit EF; Huitema ADR; Steeghs N
Clin Pharmacol Ther; 2021 Feb; 109(2):394-402. PubMed ID: 32686074
[TBL] [Abstract][Full Text] [Related]
36. Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.
Hu H; Qing Lin W; Zhu Q; Wen Yang X; Wang HD; Kuang YK
Oncotarget; 2016 Dec; 7(49):81090-81098. PubMed ID: 27835601
[TBL] [Abstract][Full Text] [Related]
37. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
[TBL] [Abstract][Full Text] [Related]
38. Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
Waterhouse D; Iadeluca L; Sura S; Wilner K; Emir B; Krulewicz S; Espirito J; Bartolome L
Target Oncol; 2022 Jan; 17(1):25-33. PubMed ID: 34964940
[TBL] [Abstract][Full Text] [Related]
39. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis.
Vuong HG; Nguyen TQ; Nguyen HC; Nguyen PT; Ho ATN; Hassell L
Target Oncol; 2020 Oct; 15(5):589-598. PubMed ID: 32865687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
